Company profile: Biovica
1.1 - Company Overview
Company description
- Provider of blood-based biomarker assays to help oncologists monitor cancer progression, including the DiviTum® TKa Test measuring cell proliferation from solid tumors, and pharma services offering TKa testing for dose-response information, patient selection, and treatment monitoring.
Products and services
- DiviTum® TKa Test: Engineered, blood-based assay that monitors cancer progression by measuring cell proliferation from solid tumors to aid oncologists
- Patient Selection and Treatment Monitoring (Pharma Services): Biomarker-guided services for pharmaceutical companies, offering patient selection and treatment monitoring capabilities using TKa testing insights
- TKa Dose-Response Testing (Pharma Services): TKa-focused testing delivered to pharmaceutical companies to generate dose-response information supporting compound evaluation and study design decisions
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Biovica
Xspray Pharma
HQ: Sweden
Website
- Description: Provider of improved and generic versions of marketed protein kinase inhibitors, using patented Hynap Technology to create amorphous formulations for faster post-patent entry. Portfolio includes Dasynoc (improved dasatinib for CML/ALL with lower dose, reduced absorption variability, and gastric acid suppressant compatibility), XS004 (dasatinib), and XS025 (cabozantinib for renal cell carcinoma and other cancers).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xspray Pharma company profile →
Cero Therapeutics
HQ: United States
Website
- Description: Provider of cellular immunotherapy centered on a CER T-cell platform that integrates anti-tumor capabilities of the innate and adaptive immune systems into a single T cell, aimed at treating hematologic malignancies and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cero Therapeutics company profile →
Cernostics
HQ: United States
Website
- Description: Provider of molecular diagnostic tests for cancer, leveraging its patent-protected TissueCypher platform. TissueCypher is a laboratory-developed test that analyzes tissue from Barrett's esophagus biopsies to provide a patient's five-year risk of progression to high-grade dysplasia or esophageal adenocarcinoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cernostics company profile →
Iambic Therapeutics
HQ: United States
Website
- Description: Provider of an AI-driven drug-discovery platform to optimize drug profiles and identify novel mechanisms of action, featuring NeuralPlexer (3D physics-based generative diffusion for protein-ligand structures), OrbNet (protein-ligand binding energetics), PropANE (multi-parameter lead selection), and Magnet (generative molecular design), plus a first-in-class CDK2/4 candidate for cyclin D- and E-driven cancers with reduced off-target toxicities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iambic Therapeutics company profile →
T3 Pharmaceuticals
HQ: Switzerland
Website
- Description: Provider of innovative bacterial cancer therapies using engineered live bacteria to deliver immune-modulating proteins directly to cancer cells and the tumor micro-environment. Offers a proprietary bacterial cancer therapy platform and develops T3P-Y058-739, a lead candidate delivering proteins into solid tumors to induce a specific immune response.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T3 Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Biovica
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Biovica
2.2 - Growth funds investing in similar companies to Biovica
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Biovica
4.2 - Public trading comparable groups for Biovica
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →